STADA takes clear lead in Russian consumer healthcare sector | STADA
Moderna on X: "This morning, we announced that the first participant has been dosed in the Phase 1/2 study of our vaccine candidate against COVID-19 in Japan, led by Takeda. Read more:
EMD Serono and Takeda Join Rancho Biosciences as Charter Members of the Spatial Innovation Initiative | Newswire
Takeda Announces FDA Accelerated Approval of ALUNBRIGTM (brigatinib) | Business Wire
Takeda Pharmaceutical (TAK) Stock Latest News - TAK News Today
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals | World Pharma Today
F-star, an invoX Company (@Fstar_Inc) / X
MIT-Takeda Program heads into fourth year with crop of 10 new projects | MIT News | Massachusetts Institute of Technology
Dais World - Press Release
2023-24 Takeda Fellows: Advancing research at the intersection of AI and health | MIT News | Massachusetts Institute of Technology
Takeda pledges $770M for plasma-derived therapy plant in Japan
STADA takes clear lead in Russian consumer healthcare sector | STADA
Press Release: Katsuhiko Takeda Appointed Executive Director of ChildFund Japan - ChildFund Alliance
Takeda Eastern Europe partners with MedUniverse to Launch A Digital HCP Engagement Plan - MedUniverse
Veeva Summit: Why Takeda is taking ownership of its technology
Takeda inaugure une nouvelle unité de production biotechnologique de pointe sur son site de Lessines en Belgique
TAKEDA - Domain Therapeutics Group
Press Releases | Takeda Pharmaceuticals
Takeda Recognized as one of the Global 100 Most Sustainable Corporations for second consecutive year | World Pharma Today
2022-23 Takeda Fellows: Leveraging AI to positively impact human health | MIT News | Massachusetts Institute of Technology
Takeda inaugure une nouvelle unité de production biotechnologique de pointe sur son site de Lessines en Belgique
FDA approves Takeda's colorectal cancer drug Fruzaqla - Pharmaceutical Technology
Takeda Oncology on LinkedIn: ADCETRIS receives EC Approval in Frontline Stage III Hodgkin Lymphoma
Form 6-K TAKEDA PHARMACEUTICAL For: Aug 23
